These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34159191)

  • 21. Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.
    Zacher A; Kaulich K; Stepanow S; Wolter M; Köhrer K; Felsberg J; Malzkorn B; Reifenberger G
    Brain Pathol; 2017 Mar; 27(2):146-159. PubMed ID: 26919320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Droplet digital PCR assay for detecting TERT promoter mutations in patients with glioma.
    Adachi JI; Shirahata M; Suzuki T; Mishima K; Uchida E; Sasaki A; Nishikawa R
    Brain Tumor Pathol; 2021 Jul; 38(3):201-209. PubMed ID: 34128111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinicopathological and molecular genetic characteristics of adult IDH wild-type diffuse gliomas].
    Wang LM; Wang W; Liu L; Gao M; Yao YY; Zhang M; Xiong YL; Shao Y; Lu DH; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2021 Jul; 50(7):734-739. PubMed ID: 34405606
    [No Abstract]   [Full Text] [Related]  

  • 25. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
    Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
    Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
    Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of IDH1 and TERT promoter mutations with droplet digital PCR in diffuse gliomas.
    Ge J; Liu MY; Li L; Deng Q; Liu F; Luo Y; Wang L; Yao G; Zhu D; Lu H; Liang M; Deng S; Zhou R; Luo T
    Int J Clin Exp Pathol; 2020; 13(2):230-238. PubMed ID: 32211103
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
    Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
    [No Abstract]   [Full Text] [Related]  

  • 30. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Prognostic Implications of 1p/19q,
    Yang Z; Ling F; Ruan S; Hu J; Tang M; Sun X; Long W
    Cancer Manag Res; 2021; 13():8755-8765. PubMed ID: 34849029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
    Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
    Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas.
    Zhang Z; Chan AK; Ding X; Li Y; Zhang R; Chen L; Liu Y; Wang Y; Xiong J; Ng HK; Yao Y; Zhou L
    Neuro Oncol; 2017 Jul; 19(7):1008-1010. PubMed ID: 28874004
    [No Abstract]   [Full Text] [Related]  

  • 34.
    Kikuchi Z; Shibahara I; Yamaki T; Yoshioka E; Shofuda T; Ohe R; Matsuda KI; Saito R; Kanamori M; Kanemura Y; Kumabe T; Tominaga T; Sonoda Y
    Neurooncol Adv; 2020; 2(1):vdaa114. PubMed ID: 33134923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telomerase reverse transcriptase promoter mutation- and O
    Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
    Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Sensitive Detection of Telomerase Reverse Transcriptase Promoter Mutation by Amplification Refractory Mutation System-PCR.
    Liu J; Zhao Z; Sun M; Chen K; Yuan W; Jiang G
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):90-3. PubMed ID: 26741813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
    Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
    Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing.
    Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A
    Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.